GSA Capital Partners LLP Trims Stock Position in Vera Therapeutics, Inc. (NASDAQ:VERA)

GSA Capital Partners LLP cut its stake in Vera Therapeutics, Inc. (NASDAQ:VERA) by 62.6% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 12,113 shares of the company’s stock after selling 20,287 shares during the period. GSA Capital Partners LLP’s holdings in Vera Therapeutics were worth $535,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Vera Therapeutics by 21.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,983 shares of the company’s stock valued at $86,000 after buying an additional 350 shares during the last quarter. Public Employees Retirement Association of Colorado purchased a new stake in shares of Vera Therapeutics in the second quarter valued at about $135,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Vera Therapeutics in the second quarter valued at about $163,000. Ameritas Investment Partners Inc. raised its holdings in shares of Vera Therapeutics by 20.8% in the first quarter. Ameritas Investment Partners Inc. now owns 4,000 shares of the company’s stock valued at $172,000 after buying an additional 688 shares during the last quarter. Finally, Cetera Advisors LLC purchased a new stake in shares of Vera Therapeutics in the first quarter valued at about $235,000. 99.21% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

VERA has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. boosted their price target on shares of Vera Therapeutics from $72.00 to $75.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 5th. Scotiabank initiated coverage on shares of Vera Therapeutics in a research note on Wednesday, October 16th. They set a “sector outperform” rating and a $60.00 price target on the stock. Cantor Fitzgerald reiterated an “overweight” rating and set a $107.00 price target on shares of Vera Therapeutics in a research note on Tuesday, October 1st. Evercore ISI upgraded shares of Vera Therapeutics to a “strong-buy” rating in a research note on Monday, September 16th. Finally, Guggenheim boosted their price target on shares of Vera Therapeutics from $56.00 to $64.00 and gave the stock a “buy” rating in a research note on Monday, October 28th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, Vera Therapeutics currently has an average rating of “Buy” and a consensus target price of $57.88.

Insider Transactions at Vera Therapeutics

In other news, CEO Marshall Fordyce sold 23,125 shares of the stock in a transaction on Wednesday, September 25th. The shares were sold at an average price of $46.05, for a total value of $1,064,906.25. Following the completion of the sale, the chief executive officer now owns 307,972 shares of the company’s stock, valued at $14,182,110.60. This represents a 6.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Beth C. Seidenberg sold 15,000 shares of the firm’s stock in a transaction on Monday, October 28th. The shares were sold at an average price of $48.03, for a total transaction of $720,450.00. Following the sale, the director now directly owns 131,553 shares of the company’s stock, valued at approximately $6,318,490.59. The trade was a 10.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 89,927 shares of company stock valued at $3,800,796 over the last 90 days. Corporate insiders own 21.70% of the company’s stock.

Vera Therapeutics Price Performance

Vera Therapeutics stock opened at $45.90 on Wednesday. Vera Therapeutics, Inc. has a 52-week low of $12.28 and a 52-week high of $51.61. The firm has a fifty day moving average of $42.87 and a 200-day moving average of $39.47. The firm has a market capitalization of $2.91 billion, a P/E ratio of -17.59 and a beta of 1.03. The company has a quick ratio of 13.76, a current ratio of 13.76 and a debt-to-equity ratio of 0.17.

Vera Therapeutics (NASDAQ:VERA) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by ($0.21). As a group, analysts predict that Vera Therapeutics, Inc. will post -2.84 EPS for the current year.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.